Go Pro
NYSEARCA:LABU

Direxion Daily S&P Biotech Bull 3x Shares (LABU) Price, Holdings, & News

Direxion Daily S&P Biotech Bull 3x Shares logo
$303.45 0.00 (0.00%)
As of 07/2/2026 04:10 PM Eastern

About Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU)

Advanced

Key Stats

Today's Range
$282.16
$305.09
50-Day Range
$156.84
$303.45
52-Week Range
$56.75
$305.09
Volume
523,223 shs
Average Volume
626,698 shs
Market Capitalization
$688.83 million
Assets Under Management
$705.58 million
Dividend Yield
0.33%
Net Expense Ratio
0.93%
Aggregate Rating
Moderate Buy

ETF Overview

Direxion Daily S&P Biotech Bull 3x Shares Expenses

TypeLABUHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.75%0.56%0.57%0.51%0.53%
Other Expenses0.18%0.47%0.55%0.58%0.55%
Total Expense0.93%0.74%0.76%0.74%0.73%
Fee Waiver0.00%-0.71%-0.64%-0.70%-0.62%
Net Expense0.93%0.59%0.63%0.58%0.60%
Receive LABU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Direxion Daily S&P Biotech Bull 3x Shares and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LABU ETF News Headlines

Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.tc pixel
See More Headlines

LABU ETF - Frequently Asked Questions

Direxion Daily S&P Biotech Bull 3x Shares' stock was trading at $159.39 at the beginning of the year. Since then, LABU stock has increased by 90.4% and is now trading at $303.45.

Direxion Daily S&P Biotech Bull 3x Shares's stock reverse split on the morning of Monday, December 4th 2023.The 1-20 reverse split was announced on Monday, December 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of LABU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Direxion Daily S&P Biotech Bull 3x Shares investors own include Micron Technology (MU), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), AT&T (T), Direxion Daily Semiconductors Bull 3x Shares (SOXL) and Advanced Micro Devices (AMD).

Fund Details

Issuer
Direxion
Fund Name
Direxion Daily S&P Biotech Bull 3x Shares
Tax Classification
Regulated Investment Company
Stock Exchange
NYSEARCA
Current Symbol
NYSEARCA:LABU
Inception Date
5/28/2015
Fund Manager
Paul Brigandi, Tony Ng
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
S&P Biotechnology Select Industry Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
165

Fund Statistics

Assets Under Management
$705.58 million
Average Daily Volume
$669.66 thousand
Discount/Premium
-0.09%
Leveraged
3.00

Administrator, Advisor and Custodian

Administrator
U.S. Bancorp Fund Services, LLC
Advisor
Rafferty Asset Management, LLC
Custodian
The Bank of New York Mellon Corporation
Distributor
Foreside Fund Services, LLC
Transfer Agent
The Bank of New York Mellon Corporation
Trustee
N/A
Lead Market Maker
Virtu Financial

Options

Optionable
Optionable
Options Volume
1,876
Put Options
779
Call Options
1,097
Short Interest
520,029 shs

Miscellaneous

Beta
2.39
Creation Unit
50,000
Creation Fee
$250.00
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Top 10 LABU Holdings

  • Dreyfus Govt Cash Man Ins
    Holding Weight: 26.83%
  • Goldman Finl Sq Trsry Inst 506
    Holding Weight: 15.94%
  • S&P Biotechnology Select Industry Index Swap
    Holding Weight: 9.47%
  • S&P Biotechnology Select Industry Index Swap
    Holding Weight: 7.35%
  • S&P Biotechnology Select Industry Index Swap
    Holding Weight: 6.75%
  • S&P Biotechnology Select Industry Index Swap
    Holding Weight: 4.85%
  • S&P Biotechnology Select Industry Index Swap
    Holding Weight: 3.87%
  • Goldman Sachs Fin Gov 465 Institut
    Holding Weight: 3.42%
  • S&P Biotechnology Select Industry Index Swap
    Holding Weight: 2.19%
  • Apogee Therapeutics (NASDAQ:APGE)
    Holding Weight: 0.76%

LABU Sector Exposure

LABU Industry Exposure


This page (NYSEARCA:LABU) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners